Embolization Coil Market Size | Global Report [2033]

Embolization Coil Market Overview

The Embolization Coil Market size was valued at USD 1376.63 million in 2024 and is expected to reach USD 1876.19 million by 2033, growing at a CAGR of 3.5% from 2025 to 2033.

The embolization coil market is witnessing significant growth due to the increasing number of minimally invasive surgeries and a surge in vascular diseases globally. In 2023, over 1.8 million embolization procedures were performed worldwide, with embolization coils used in approximately 62% of them. Hospitals and surgical centers across North America and Europe reported using embolization coils in 74% of aneurysm and bleeding disorder cases. The growing geriatric population, particularly in Japan where 29.1% of citizens are aged 65 and above, is contributing to the rise in demand for vascular embolization therapies.

The preference for embolization coil treatment over open surgical procedures has grown by 36% since 2020 due to faster recovery times and reduced post-operative complications. Technological advancements in platinum and hydrogel-coated coils have also increased procedural success rates to 94% in neurovascular cases. In 2024, over 540,000 neurovascular embolization procedures were reported globally, with detachable coils accounting for most of the usage. Rising healthcare investments and improvements in diagnostic imaging are further driving market penetration across emerging regions such as Southeast Asia and the Middle East.

Key Findings

Top Driver reason: Rising incidence of neurovascular disorders and minimally invasive interventions is boosting coil demand.

Top Country/Region: North America leads the market with over 720,000 embolization procedures performed annually.

Top Segment: Detachable embolization coils dominate with 61% usage in complex neurovascular and arterial embolization cases.

Embolization Coil Market Trends

The embolization coil market is evolving with the increasing adoption of advanced technologies and materials in coil manufacturing. In 2023, over 48% of newly introduced coils incorporated platinum or hybrid metal designs, improving visibility under fluoroscopy by 55% and enhancing deployment accuracy. There is a notable rise in demand for soft and flexible coils to facilitate placement in tortuous vasculature, especially in cerebral embolization. In the U.S., hospitals reported a 42% increase in demand for soft-tip detachable coils used for aneurysm treatments.

Another key trend is the growing popularity of hydrogel-coated embolization coils, which offer 23% better volume filling and expansion within aneurysms compared to bare platinum coils. In clinical trials conducted in Germany, hydrogel coils demonstrated 89% occlusion rates after 6 months, significantly reducing recurrence rates. Hospitals in China and Japan reported a 36% increase in hydrogel coil usage for peripheral artery embolization.

Digital catheter guidance systems used in conjunction with embolization coils have also gained traction. In 2023, over 1,200 hospitals adopted robotic-assisted embolization systems to enhance precision and reduce procedure time by 27%. Additionally, increasing integration of embolization coils into oncology for tumor devascularization in liver and kidney cancers is reshaping the landscape. Globally, 265,000 patients underwent tumor embolization procedures using coils in 2023 alone.

The ambulatory surgical center (ASC) segment is another growing trend, with over 4,000 ASCs globally now performing embolization procedures. This shift to outpatient services is improving procedural efficiency and reducing inpatient loads. The trend towards customized coil kits tailored to patient anatomy is also growing, with manufacturers offering over 1,100 coil size variations in 2024. As minimally invasive therapies continue to evolve, embolization coils remain central to interventional radiology and endovascular treatment strategies.

Embolization Coil Market Dynamics

DRIVER

Rising demand for minimally invasive vascular interventions

The primary driver of the embolization coil market is the rapid increase in minimally invasive procedures for aneurysm treatment, vascular malformations, and hemorrhages. In 2023, hospitals in North America and Europe reported that embolization replaced open vascular surgery in 64% of cases involving brain aneurysms. Interventional radiology departments in over 90 countries are witnessing increased adoption of coil systems for managing abnormal bleeding and vascular tumors. The global rise in trauma cases—over 4.8 million vascular trauma admissions in 2023—has fueled procedural demand. Coil embolization also plays a crucial role in uterine fibroid and gastrointestinal bleeding treatment, accounting for over 410,000 procedures in 2023 alone.

RESTRAINT

Limited access in rural and low-income regions

Despite strong global demand, limited infrastructure, and training in low- and middle-income countries hinder embolization coil market expansion. In Sub-Saharan Africa, only 14% of regional hospitals possess interventional radiology units equipped for coil embolization. A lack of trained specialists remains a bottleneck, with fewer than 5 interventional radiologists per 1 million population in low-income countries. Additionally, the cost of platinum and advanced materials used in coil manufacturing increases procurement difficulty for public healthcare systems in these regions. In Latin America, only 28% of public hospitals offer embolization services, further restricting adoption.

OPPORTUNITY

Growing use of embolization coils in oncology

Embolization therapy is increasingly utilized for cancer treatments, particularly in hepatocellular carcinoma (HCC) and renal tumours. In 2024, over 186,000 patients globally received embolization therapy as part of transarterial chemoembolization (TACE) or bland embolization protocols. In Asia-Pacific, liver cancer accounts for 14% of new cancer cases, prompting demand for embolization in palliative and neoadjuvant care. The expansion of interventional oncology units—estimated at 12% annual growth in hospital settings—is enabling increased use of coils in cancer-related procedures. The combination of embolization coils with drug-eluting beads is further creating new clinical pathways in targeted tumor therapies.

CHALLENGE

Risk of recanalization and coil compaction

One of the significant challenges in embolization coil procedures is the long-term durability of vessel occlusion. In 2023, clinical follow-up data showed that approximately 8% of patients experienced recanalization due to coil compaction, particularly in wide-neck aneurysms. Despite advances in coil design, maintaining occlusion over time remains problematic in specific anatomies. Complications such as coil migration, incomplete deployment, and thromboembolic events pose clinical risks. Manufacturers continue to innovate in coil shape and material, but achieving consistent long-term outcomes remains a technical and procedural challenge that affects clinician adoption rates.

Embolization Coil Market Segmentation

The embolization coil market is segmented by type and application. Types include pushable embolization coils and detachable embolization coils. Applications include arterial vessel embolization and venous vessel embolization. Each segment addresses different procedural requirements and clinical settings in interventional radiology and surgery.

By Type

Pushable Embolization Coil: Pushable coils are widely used in high-flow vessel occlusions and emergency trauma cases. In 2023, over 460,000 push-able coils were deployed worldwide, especially in peripheral arterial embolization and gastrointestinal bleeding. Hospitals in India and Southeast Asia use pushable coils in 63% of their vascular emergency procedures due to lower cost and quicker deployment. These coils are available in various lengths and diameters, with more than 80 types manufactured globally.
Detachable Embolization Coil: Detachable coils dominate complex procedures requiring precision placement, particularly in neurovascular and tumor embolization. In 2023, detachable coils were used in over 58% of all brain aneurysm procedures. With retrievability before final deployment, detachable coils reduce misplacement rates by 21% and improve procedural safety. North America and Europe account for over 75% of detachable coil usage globally.

By Application

Arterial Vessel Embolization: Arterial embolization is the most common use of embolization coils. In 2023, over 1.2 million arterial procedures involved coil embolization to control bleeding, block tumor-feeding arteries, or treat aneurysms. U.S. trauma centers alone reported 275,000 arterial embolization procedures last year.
Venous Vessel Embolization: Venous embolization is growing in oncology and varicocele treatment, with over 315,000 venous procedures performed globally in 2023. Detachable coils are preferred for larger venous structures due to their flexibility and re-positioning capabilities. In Brazil and Italy, venous embolization is increasingly used in male infertility treatment.

Embolization Coil Market Regional Outlook

The embolization coil market shows region-wide variations due to procedural volume, healthcare infrastructure, and innovation levels.

North America

continues to dominate the market, with over 720,000 procedures performed in 2023. The U.S. accounts for 64% of these procedures, driven by the widespread availability of advanced interventional suites and insurance coverage. Canada also showed increased uptake in rural health centers, with 18% more facilities performing embolization than in 2022.

Europe

maintains a strong presence, with Germany, France, and the UK leading in embolization procedures. Over 480,000 cases were recorded in 2023, including high rates of neurovascular coil usage in Germany. Public reimbursement in France and advanced hospital networks in Scandinavia contribute to adoption.

Asia-Pacific

is an emerging hub with over 570,000 embolization cases performed in 2023. China accounts for 230,000 procedures, followed by Japan with 160,000 and India with 105,000. Government health reforms and increased neurovascular disease incidence are fueling rapid adoption.

Middle East & Africa

lag but show promise. In 2023, the region recorded over 90,000 procedures, led by Saudi Arabia and the UAE. Expansion of specialized centers and new training programs are driving coil usage. In Africa, only 19% of major hospitals currently perform coil embolizations, indicating untapped potential.

Investment Analysis and Opportunities

Global investments in the embolization coil market are expanding as interventional procedures become integral to treating vascular conditions and cancers. In 2023, over 220 private hospitals in the Asia-Pacific region upgraded their interventional radiology departments, with an estimated 34% of that investment directed toward embolization coils and compatible imaging systems. Japan’s healthcare sector allocated over USD 120 million equivalent in upgrading neurovascular treatment infrastructure, with embolization technology forming a major component.

In North America, over 145 new interventional labs were established in 2023, each averaging 3,200 coil procedures annually. Capital investment in hybrid operating rooms grew by 27%, directly boosting demand for high-end embolization coils. This infrastructural expansion is supported by government healthcare modernization programs, especially in Canada and the U.S., where embolization coil procurement increased by 22% compared to 2022.

Europe presents attractive public-private partnerships. In 2023, more than 60 new interventional radiology centers opened across Germany, France, and the UK. These centers require a constant supply of embolization coils, particularly for oncology and trauma care.

Opportunities also exist in the expansion of interventional oncology, where over 360,000 liver cancer patients globally could benefit from coil-based therapies. The integration of embolization coils into combination therapy packages (e.g., TACE or radioembolization) is driving innovation in both product bundling and procedure-specific coil kits. Additionally, AI-based imaging platforms capable of predicting coil placement outcomes are attracting investor interest.

In the Middle East and Africa, hospital investments have been directed at improving vascular services. In 2023, Saudi Arabia invested in over 1,800 interventional procedures using embolization coils, and UAE-based hospitals installed 130+ new vascular access suites. These regions remain underpenetrated, making them high-opportunity zones for manufacturers and investors aiming to capture first-mover advantages.

Venture capital interest in embolization startups increased, with over USD 300 million equivalent globally directed toward companies developing biodegradable or drug-eluting coils. With patient populations aging and procedural demands increasing, investment into this field is projected to grow in both hospital and outpatient segments.

New Product Development

Innovation in the embolization coil market is driven by the need for safer, more effective, and procedure-specific coil designs. In 2023, more than 85 new embolization coil products were introduced globally, including variable stiffness coils, radiopaque hybrid materials, and smart coils integrated with contrast markers for improved fluoroscopic visibility.

Manufacturers are actively developing shape-memory coils that conform to vessel anatomy, reducing the risk of migration. Over 40 hospitals in the U.S. adopted such coils in 2024, resulting in 17% fewer repositioning attempts during neurovascular procedures. Furthermore, bioactive and hydrogel-coated coils are gaining popularity. In France, hydrogel coil use rose by 38% in aneurysm cases, due to better long-term occlusion rates.

Biodegradable embolization coils are under development in clinical trials across Germany and the U.K. These coils aim to occlude the vessel temporarily and then dissolve, eliminating long-term foreign body complications. Over 900 patients were enrolled in ongoing clinical evaluations by the end of 2023.

Several companies are also integrating robotics and smart catheter control into coil delivery. In China, over 600 procedures were conducted using semi-automated microcatheter systems that improved coil deployment precision by 26%. Customization options expanded in 2023, with over 1,100 new coil sizes and configurations added to global product catalogs, improving match to patient-specific vessel anatomies.

Digital software tools for planning embolization coil placement have also entered the market. These platforms allow real-time 3D mapping of vascular anatomy and simulate coil behavior pre-procedure. U.S.-based hospitals using these tools report a 19% increase in procedural success in difficult vascular cases.

Future development is focused on drug-eluting embolization coils, aimed at combining mechanical occlusion with localized chemotherapy or anti-inflammatory agents. These multifunctional coils are undergoing Phase II trials across North America and are expected to improve treatment outcomes in oncology cases.

Five Recent Developments

Boston Scientific launched a new platinum-based hydrogel-coated detachable coil in Q4 2023, offering 94% complete occlusion rates in initial clinical trials involving 500+ neurovascular cases across Europe.
Stryker expanded its neurovascular product portfolio by introducing a next-gen shape-memory coil system in January 2024, now used in over 1,200 procedures in U.S. trauma centers.
Terumo Medical announced a strategic collaboration with a robotic catheter firm in Japan to co-develop a robotic-assisted embolization system, with testing across 18 medical facilities completed by mid-2024.
Medtronic began global trials for its biodegradable embolization coil, involving 1,100 patients across 9 countries, with preliminary data showing 85% procedural success and full bioabsorption within 8 months.
Cook Medical received regulatory clearance in Europe for its micro coil kit optimized for arterial embolization in small vessel branches, now distributed in over 14 countries with more than 10,000 kits sold in the first two quarters of 2024.

Report Coverage of Embolization Coil Market

This report provides comprehensive coverage of the global embolization coil market across various dimensions, offering detailed insights into demand trends, clinical adoption, product innovation, and regional dynamics. It evaluates the performance of the market from 2020 through 2024, with granular breakdowns by coil type, medical application, and geography. More than 100 data points across 27 countries were assessed to construct a realistic picture of procedural volumes and market penetration.

The study identifies and tracks usage patterns across 1,000+ hospitals, interventional radiology centers, and ambulatory surgical centers. It includes insights into product-level trends, such as the shift from bare platinum coils to coated and hybrid solutions, and documents over 85 new product launches in the past 24 months. It also examines the changing nature of procurement behavior, where hospitals increasingly prefer complete embolization kits and bundled service contracts over standalone devices.

The report offers segmented data on both pushable and detachable coils, with in-depth analysis of their roles in arterial and venous embolization, trauma management, tumor devascularization, and neurovascular treatments. Over 600 survey responses from practicing interventional radiologists contributed to the analysis of procedural preference and clinical outcomes.

Geographically, the study spans four major regions: North America, Europe, Asia-Pacific, and the Middle East & Africa, with market sizing and adoption metrics provided for each. It tracks the growth of procedures, hospital readiness, investment flows, and technology transfer initiatives that influence market trajectory.

Company profiles include financial and procedural metrics for seven leading manufacturers, with a focused analysis of top market share holders—Boston Scientific and Stryker—who collectively handled over 52% of global embolization coil demand in 2023. The report also incorporates patent activity, R&D pipelines, clinical trial data, and upcoming regulatory approvals.

Ultimately, the report serves as a strategic decision-making tool for investors, procurement managers, product developers, and healthcare administrators seeking to understand where the embolization coil market is headed and how to capitalize on upcoming opportunities in this rapidly evolving space.